Edition:
United States

Profile: Avadel Pharmaceuticals PLC (AVDL.OQ)

AVDL.OQ on NASDAQ Stock Exchange Global Market

4.35USD
4:00pm EDT
Change (% chg)

$-0.35 (-7.45%)
Prev Close
$4.70
Open
$4.73
Day's High
$4.73
Day's Low
$4.29
Volume
71,168
Avg. Vol
73,601
52-wk High
$11.91
52-wk Low
$4.29

Avadel Pharmaceuticals, PLC is a specialty pharmaceutical company. The Company offers various drug delivery platforms, including Micropump, LiquiTime, Trigger Lock and Medusa. Micropump is a microparticulate system that allows the development of modified and/or controlled release of solid, oral dosage formulations of drugs. LiquiTime uses Micropump’s competitive advantages to allow development of modified/controlled release liquid suspension formulations. TriggerLock is a drug delivery platform with the potential to provide a controlled release of opioid analgesics. Medusa is a hydrogel depot technology that allows a delivery, resulting in treatment adherence.

The Company offers its products in various categories, such as hospital, including Bloxiverz, Vazculep and Akovaz, and pediatrics, including Karbinal ER, Cefaclor for Oral Suspension, AcipHex Sprinkle and Flexichamber. Bloxiverz is a drug used intravenously in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery. Vazculep is used to treat clinically hypotension resulting primarily from vasodilation in the setting of anesthesia. Akovaz is indicated to treat clinically hypotension in the setting of anesthesia. Karbinal ER, a Histamine 1 (H1) receptor antagonist (antihistamine) indicated for children over two years of age. Karbinal ER provides physicians to use treatment option for children with seasonal and perennial allergic rhinitis that need symptomatic relief for runny nose, sneezing, and itchy skin. Cefaclor is indicated for the treatment of otitis media, lower respiratory infections, pharyngitis and tonsillitis, urinary tract infections, and skin and skin structure infections, caused by susceptible organisms.

ACIPHEX Sprinkle (rabeprazole sodium delayed-release capsules) is a proton-pump inhibitor (PPI) indicated for the treatment of gastroesophageal reflux disease (GERD) in pediatric patients in a range of 1 to 11 years of age. Flexichamber is a collapsible holding chamber to administer aerosolized medication from pressurized Metered Dose Inhalers (pMDIs). Flexichamber is comprised of anti-static materials to help delivery of medication from MDIs to the patient, while managing the medication to the walls of the chamber. Flexichamber is an anti-static valved collapsible holding chamber intended to be used by patients under the care or treatment of a physician or licensed healthcare professional.

The Company competes with Alkermes plc, COSMO Pharmaceuticals SpA, Depomed, Inc., Durect Corp., Supernus Pharmaceuticals, Inc., Veloxis Pharmaceuticals A/S, Neos Therapeutics, Inc., Tris Pharma, Inc., Acura Pharmaceuticals, Inc., Altus Formulation, Cephalon, Collegium Pharmaceutical, Inc., Egalet Corporation, Elite Pharmaceuticals, Inc., Ethypharm, Grunenthal Group, Intellipharmaceutics International, Inc., QRx Pharma, Ltd., KemPharm, Inc., Biodel Inc., Debiopharm Group, LG Life Sciences, InnoCore Pharmaceuticals, Marina Biotech, Inc., MedinCell SA, Dr. Reddy’s, Onxeo, Pacira Pharmaceuticals, Inc., Midatech, REcoly N.V., Soligenix, Inc., Surmodics, Inc. and Xenetic Biosciences plc.

Company Address

Avadel Pharmaceuticals PLC

Blanchardstown Corporate Park, B
DUBLIN     15
P: +3531.4851200
F: +3531.5261077

Company Web Links